Navigation Links
Pregnancy-related hormonal changes linked to increased risk of restless legs syndrome

Westchester, Ill. A study in the Feb. 1 issue of the journal Sleep shows that the elevation in estradiol levels that occurs during pregnancy is more pronounced in pregnant women with restless legs syndrome (RLS) than in controls.

During the last trimester of pregnancy, levels of the estrogenic steroid hormone estradiol were 34,211 pg/mL in women with RLS and 25,475 pg/mL in healthy controls. At three months postpartum, estradiol levels had dropped to 30.73 pg/mL in the RLS group and 94.92 pg/mL in controls. Other hormone levels did not differ significantly between the study groups.

According to the authors the data strongly suggest that estrogens play an important role in RLS during pregnancy. The study also supports previous reports of high RLS incidence in the last trimester of pregnancy when estradiol is maximally elevated.

"Our findings strongly support the concept that neuroactive hormones play a relevant pathophysiological role in RLS," said principal investigator Thomas Pollmacher, MD, director of the Center for Medical Health at Klinikum Ingolstadt and professor of psychiatry at Ludwig Maximilians University in Munich, Germany. "This information will increase the understanding of RLS in pregnancy and will assist in the development of specific therapeutic approaches."

The American Academy of Sleep Medicine describes RLS as a sleep-related movement disorder that involves an almost irresistible urge to move the legs at night. This urge tends to be accompanied by unusual feelings or sensations, called "paresthesias," that occur deep in the legs. These uncomfortable sensations often are described as a burning, tingling, prickling or jittery feeling. RLS can profoundly disturb a person's ability to go to sleep or return to sleep after an awakening.

The AASM reports that RLS occurs 1.5 to two times more often in women than in men. Eighty percent to 90 percent of people with RLS also experience periodic limb movements (PLMs) during sleep, which are involuntary jerking or twitching movements of the feet or legs.

According to the authors RLS symptoms often occur for the first time during pregnancy. Symptoms typically worsen during pregnancy and improve or even disappear after delivery. The risk of developing RLS increases gradually with the number of pregnancies.

The study also found that women with RLS had more PLMs than controls before and after delivery. PLMs decreased significantly after delivery in women with RLS and stayed low in women without RLS.

Only minor differences appeared between the two study groups in subjective sleep quality and objective sleep measures. One explanation suggested by the authors is that only RLS patients who did not need pharmacological treatment were selected for the study; RLS symptoms of participants were in the mild to moderate range.

The study involved nine healthy pregnant women (mean age 32.9 years) who were placed in a control group and 10 pregnant women (mean age 31.6 years) who fulfilled diagnostic criteria for RLS. Eight women from the RLS group reported symptoms previous to the present pregnancy, and all members of the RLS group described worsening of symptoms during pregnancy. The mean age of onset for RLS symptoms was 22.6 years.

Sleep data and leg movements were recorded during overnight polysomnography around the 36th week of gestation and again at 12 weeks postpartum. Blood samples were taken each morning after the polysomnography and before breakfast. Accompanying questionnaires on sleep and RLS symptoms also were collected.


Contact: Kelly Wagner
American Academy of Sleep Medicine

Related medicine news :

1. 15% of Women Struggle With Pregnancy-Related Depression
2. Some Pregnancy-Related Complications Minimized for Women Who Have Had Weight-Loss Surgery
3. Hormonal Changes and Depression: What is the Connection?
4. Hormonal dietary supplements might promote prostate cancer progression
5. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
6. Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract
7. Inheritance of hormonal disorder marked by excessive insulin in daughters
8. Non-Hormonal Therapies Aid Breast Cancer Patients
9. Arbios Announces Management Changes
10. Renovis Announces Management Changes
11. Bradmer announces management changes
Post Your Comments:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... While it’s ... poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , ... medication in darkness or restricted lighting. As such, it eliminates the need to turn ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
Breaking Medicine Technology: